Compare KRYS & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRYS | CYTK |
|---|---|---|
| Founded | 2015 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8B | 7.6B |
| IPO Year | 2017 | 2004 |
| Metric | KRYS | CYTK |
|---|---|---|
| Price | $262.33 | $65.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 18 |
| Target Price | ★ $297.60 | $88.94 |
| AVG Volume (30 Days) | 217.1K | ★ 1.9M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 128.00 | N/A |
| EPS | ★ 6.84 | N/A |
| Revenue | ★ $389,130,000.00 | $13,368,000.00 |
| Revenue This Year | $39.88 | $6.88 |
| Revenue Next Year | $34.38 | $308.26 |
| P/E Ratio | $38.23 | ★ N/A |
| Revenue Growth | ★ 33.94 | N/A |
| 52 Week Low | $123.03 | $29.31 |
| 52 Week High | $298.30 | $70.98 |
| Indicator | KRYS | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 55.55 | 55.76 |
| Support Level | $251.93 | $59.12 |
| Resistance Level | $293.60 | $69.67 |
| Average True Range (ATR) | 9.28 | 2.41 |
| MACD | 2.05 | 0.51 |
| Stochastic Oscillator | 90.05 | 64.57 |
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.